Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma. We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously untreated metastatic melanoma.We randomly assigned 502 patients with previously untreated metastatic melanoma, in a 1:1...